Curis (CRIS) vs Valion Bio (VBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Valion Bio is the larger company by market cap ($2.0 million vs $1.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRIS | VBIO |
|---|---|---|
| Share price | $0.7094 | $2.21 |
| Market cap | $1.72M | $1.96M |
| 1-day change | -3.69% | +0.91% |
| P/E ratio (TTM) | 0.54 | — |
| EPS (TTM) | $1.32 | $-177.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $33.60 | $76.50 |
| 52-week low | $0.61 | $2.05 |
| Distance from 52-week high | -97.89% | -97.11% |
| Analyst consensus | none | — |
| Avg. price target upside | +5914.94% | — |
| Average volume | 199.15K | 1.46M |
| Shares outstanding | 2.43M | 887.59K |
| Employees | 20 | 52 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Curis
CRIS stock →Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma.
Healthcare · Biotechnology · 20 employees
About Valion Bio
VBIO stock →Valion Bio, Inc. operates as a late-stage biopharmaceutical company.
Healthcare · Biotechnology · 52 employees
CRIS vs VBIO FAQ
Which is bigger, Curis or Valion Bio?
Valion Bio (VBIO) is larger, with a market capitalization of $1.96M compared with $1.72M for Curis (CRIS).
Are Curis and Valion Bio in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.